Prenetics Global (NASDAQ:PRE) CFO Buys $116,280.00 in Stock

Key Points

• Prenetics Global CFO Brian Rosin bought 5,100 shares at $22.80 each, investing $116,280 and increasing his personal stake by 28.33% to 23,100 shares.
• Prenetics reported a quarterly loss of $0.53 per share, beating the $0.84 consensus estimate, but revenue of $46.49 million fell short of analysts’ $49.85 million forecast. The company remains unprofitable, with a negative 47.43% net margin.
• Analyst sentiment is moderately bullish: four analysts rate the stock a Buy and one rates it Sell, producing an average target price of $34.25 versus a recent share price of $23.25. Institutional ownership stands at 25.01%.

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) CFO Brian Rosin purchased 5,100 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were purchased at an average cost of $22.80 per share, with a total value of $116,280.00. Following the acquisition, the chief financial officer owned 23,100 shares in the company, valued at $526,680. This trade represents a 28.33% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Prenetics Global Price Performance

Shares of NASDAQ:PRE opened at $23.25 on Wednesday. Prenetics Global Limited has a 1 year low of $7.25 and a 1 year high of $23.63. The stock has a market capitalization of $392.23 million, a price-to-earnings ratio of -5.59 and a beta of 0.26. The company's 50 day simple moving average is $19.12 and its 200 day simple moving average is $18.93.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.31. The firm had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. As a group, analysts anticipate that Prenetics Global Limited will post -1.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Prenetics Global during the 3rd quarter valued at $65,000. UBS Group AG increased its holdings in Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company's stock worth $619,000 after purchasing an additional 39,733 shares in the last quarter. Kingsview Wealth Management LLC acquired a new position in Prenetics Global in the 4th quarter worth about $172,000. Goldman Sachs Group Inc. bought a new position in Prenetics Global in the fourth quarter valued at about $665,000. Finally, T3 Companies LLC bought a new position in Prenetics Global in the fourth quarter valued at about $170,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PRE. Benchmark raised their price objective on Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Wall Street Zen raised Prenetics Global from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Prenetics Global in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $34.25.

About Prenetics Global

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source